ME 1207 IN RESPIRATORY TRACT INFECTIONS

概要

論文の詳細を見る
The clinical effects of ME 1207 were evaluated in 18 patients with respiratory infections (11 patients with acute pneumonia, 2 with acute bronchitis, 1 with secondary infection in bronchiectasis and 4 with chronic bronchitis in the phase of acute exacerbation).ME 1207 was administered orally to these patients in doses of 100 to 200 mg t. i. d.The clinical response to ME 1207 was "excellent" in 3 and "good" in 8 of the 11 patients with acute pneumonia;it was "excellent" and "fair" in 1 each of 2 patients with acute bronchitis; "good" in 2, "fair" in 1 and "poor" in 1 in the 4 patients with chronic bronchitis in the phase of acute exacerbation;and it was "good" in 1 patient with bronchiectasis. Overall, the response was excellent in 3, good in 12, fair in 2 and poor in 1 of the 18 patients given ME 1207, and the rate of effectiveness was 83.3%.In the bacteriological study the eradication of 5 of 8 strains was confirmed.Adverse drug reactions were not evoked in any patient. Abnormal laboratory tests included elevated GPT in 1 case, elevated GOT and GPT in 2 cases, depressed WBC and elevated GOT and GPT in 1 case, 4 cases in all, but all changes were slight.
公益社団法人日本化学療法学会の論文